Horizon Pharma has announced that Quinsair levofloxacin inhalation solution is now available in Canada for the treatment of P. aeruginosa lung infections in adult cystic fibrosis patients. Horizon acquired Quinsair when it acquired Raptor Pharmaceutical company in October 2016. Raptor launched Quinsair in Europe in April 2016.
Horizon Pharma VP and General Manager, Canada Jared Rhines said, “Prevalence of Pseudomonas aeruginosa is high among people with cystic fibrosis and chronic management is often required after a patient is infected with these bacteria. Horizon has a long-term commitment to people living with rare diseases, and we’re looking forward to working with healthcare professionals and patient organizations that address the needs of the Canadian cystic fibrosis community at risk for these insidious infections.”
Cystic Fibrosis Canada President and CEO Norma Beauchamp commented, “It is very important that healthcare professionals in Canada have access to a variety of medicines for people with cystic fibrosis dealing with Pseudomonas aeruginosa infections. Once established in the airways, this bacteria becomes very difficult to eliminate, often requiring aggressive treatment with multiple therapies. Quinsair provides an inhaled option and we’re pleased that it is now available in Canada.”
Read the Horizon Pharma press release.
